A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Clinical Trial ID NCT01042769

PubWeight™ 9.66^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01042769

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.	JAMA	2014	1.58
2	Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus.	Diabetes Metab Syndr Obes	2014	1.05
3	PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty.	J Lipid Res	2012	1.04
4	Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects.	Am Heart J	2012	0.98
5	Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial.	PLoS One	2014	0.89
6	Comparative transcriptional network modeling of three PPAR-α/γ co-agonists reveals distinct metabolic gene signatures in primary human hepatocytes.	PLoS One	2012	0.85
7	Role of lipotoxicity in endothelial dysfunction.	Heart Fail Clin	2012	0.82
8	Refocusing Peroxisome Proliferator Activated Receptor-α: A New Insight for Therapeutic Roles in Diabetes.	Diabetes Metab J	2013	0.81
9	Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.	BMC Nephrol	2014	0.81
10	Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.	Am Heart J	2013	0.81